HY05350

HY05350 is a **trispecific T cell engager antibody** engineered to target **CD3** (T cell coreceptor), **mesothelin (MSLN)**, and **programmed death-ligand 1 (PD-L1)** for the treatment of solid tumors. The construct combines anti-CD3 (developed by affinity optimization of SP34), humanized single-domain (VHH) antibodies generated in alpaca for MSLN and PD-L1, into a trispecific format. This design aims to recruit and activate T cells at the tumor site, simultaneously targeting mesothelin-positive tumor cells and blocking the PD-1/PD-L1 immune checkpoint to enhance anti-tumor efficacy. Preclinical studies support activation of T cells, T cell-dependent cytotoxicity, checkpoint blockade function, and anti-tumor efficacy in models. Clinical development focuses on patients with **advanced mesothelin-positive solid tumors** refractory to standard treatment[1][2][3][7].

Other names

HY 05350HY05350HY-05350